Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Niraparib in newly diagnosed advanced ovarian cancer: PRIMA results

Antonio González Martín, MD, Clínica Universidad de Navarra, Madrid, Spain, presents results from the Phase III PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016) of niraparib in newly diagnosed advanced ovarian cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.